N-甲基l-N-(3-氯丙基)-3,4-二甲氧基苯乙胺 | 36770-74-8

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-甲基l-N-(3-氯丙基)-3,4-二甲氧基苯乙胺
• 中文别名: N-甲基L-N-(3-氯丙基)-3,4-二甲氧基苯胺
• 英文名称: N-(3-chloropropyl)-3,4-dimethoxy-N-methylphenethylamine
• 英文别名: 1-chloro-3-propane；3-chloro-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine；1-Chlor-3--propan；1-Chloro-3-[N-methyl-N-(2-{3,4-dimethoxyphenyl}-ethyl)amino]-propane；3-chloropropyl-(2-(3,4-dimethoxyphenyl)-ethyl)-methylamine；1-chloro-3-[N-methyl-N-(3,4.dimethoxy-β-phenethyl)amino] propane；3-[N-(2-(3,4-dimethoxyphenyl)-ethyl)-N-methylamino]-propylchloride；N-(3-chloro-propyl)-N-methyl-3,4-dimethoxy-benzenethanamine；(N-methyl-N-homoveratryl)-amino-γ-chloropropane；N-Methyl-N-(3-chloropropyl)homoveratrylamine
• CAS: 36770-74-8
• 化学式: C₁₄H₂₂ClNO₂
• 分子量: 271.787
• InChiKey: HJBBKVHYQQUPQW-UHFFFAOYSA-N

物化性质

• 沸点：
  69-70 °C(Press: 0.005 Torr)
• 密度：
  1.066±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090
• 储存条件：
  存储条件为2-8°C，并需使用惰性气体保护。

反应信息

• 作为反应物：
  描述：

  N-甲基l-N-(3-氯丙基)-3,4-二甲氧基苯乙胺 在 盐酸 、 potassium carbonate 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-[4-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]piperazine-1-carbonyl]-10H-acridin-9-one
  参考文献：
  名称：

  Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides

  摘要：

  A number of tricyclic carboxamides have been synthesized and tested to evaluate their ability to reverse multidrug resistance in the (CHC)-C-R/5 cell line. Among them the acridone derivatives were the most potent, A key feature is the presence of a dimethoxybenzyl or phenethylamine cationic site, separated from the tricyclic lipophilic part by a carbamoylphenyl chain. Optimization led to compounds 2 orders of magnitude more active than the prototype inhibitors verapamil and amiodarone. On the basis of in vitro and in vivo activities, 9,10-dihydro-5-methoxy- 9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)ethyl]phenyl]-4-acridinecarboxamide (84) has been selected for further development.

  DOI：

  10.1021/jm00013a017
• 作为产物：
  描述：

  3,4-二甲氧基苯乙胺 在 sodium hydroxide 、 potassium carbonate 、 苯甲醛 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 N-甲基l-N-(3-氯丙基)-3,4-二甲氧基苯乙胺
  参考文献：
  名称：

  Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides

  摘要：

  A number of tricyclic carboxamides have been synthesized and tested to evaluate their ability to reverse multidrug resistance in the (CHC)-C-R/5 cell line. Among them the acridone derivatives were the most potent, A key feature is the presence of a dimethoxybenzyl or phenethylamine cationic site, separated from the tricyclic lipophilic part by a carbamoylphenyl chain. Optimization led to compounds 2 orders of magnitude more active than the prototype inhibitors verapamil and amiodarone. On the basis of in vitro and in vivo activities, 9,10-dihydro-5-methoxy- 9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)ethyl]phenyl]-4-acridinecarboxamide (84) has been selected for further development.

  DOI：

  10.1021/jm00013a017
• 作为试剂：
  描述：

  N-甲基l-N-(3-氯丙基)-3,4-二甲氧基苯乙胺 、 7,8-二甲氧基-1,3-二氢-2H-3-苯并氮杂卓-2-酮 在 N-甲基l-N-(3-氯丙基)-3,4-二甲氧基苯乙胺 作用下， 以40的产率得到3-[3-[[2-(3,4-二甲氧基苯基)乙基]甲基氨基]丙基]-1,3,4,5-四氢-7,8-二甲氧基-2H-3-苯并氮杂-2-酮盐酸盐
  参考文献：
  名称：

  Tetrahedron Lett. 2003, 44, 4203-4206

  摘要：

  DOI：

文献信息

• Alkyl- or aryl-aminoalkoxy-benzene-sulfonyl indoles
  申请人：Sanofi

  公开号：US04994474A1

  公开（公告）日：1991-02-19

  The present invention relates to aminoalkoxyphenyl derivatives of formula: ##STR1## and its N-oxide and pharmaceutically acceptable salts, in which: B represents a--S--, --SO-- or --SO.sub.2 -- group, R.sub.1 and R.sub.2, which are identical or different, each denote hydrogen, a methyl or ethyl radial or a halogen atom, A denotes a straight-or branched-alkylene radical having from 2 to 5 carbon atoms or a 2-hydroxypropylene radial in which the hydroxy is optionally substituted by a lower alkyl radical, R.sub.3 denotes an alkkyl radical or a radical of formula: --Alk--Ar in which Alk denotes a single bond or a linear- or branched-alkylene radical having from 1 to 5 carbon atoms and Ar denotes a pyridyl, phenyl, 2,3-methylenedioxyphenyl or 3,4-methylenedioxyphenyl radical or a phenyl group substituted with one or more substituents, which may be identical or different, selected from halogen atoms, lower alkyl group or lower alkoxy groups, R.sub.11 denotes hydrogen or a lower alkyl, phenyl, diphenylmethyl, benzyl or halogenobenzyl radical, R.sub.4 denotes hydrogen or an alkyl radical, or R.sub.3 and R.sub.4 when taken together denote an alkylene or alkenylene radical having from 3 to 6 carbon atoms and optionally substituted with a phenyl radical or optionally interrupted by ##STR2## R represent hydrogen, an alkyl radical, a cycloalkyl radical, a benzyl radical or a phenyl radical optionally substituted with one or more substituents, which may be identical or different, selected from halogen atoms and from lower alkyl, lower alkoxy or nitro groups, are described. The compounds of the invention possess exceptional pharmacological properties, especially calcium transport inhibitory properties, as well as bradycardic, hypotensive and antiadrenergic properties.

  本发明涉及公式的氨基烷氧基苯基衍生物：##STR1##及其N-氧化物和药学上可接受的盐，其中：B代表a--S--，--SO--或--SO.sub.2--基团，R.sub.1和R.sub.2，它们相同或不同，每个代表氢，甲基或乙基基团或卤原子，A代表具有2至5个碳原子的直链或支链烷基基团或2-羟基丙烯基团，其中羟基可选择地被较低的烷基基团取代，R.sub.3代表烷基基团或公式的基团：--Alk--Ar，其中Alk代表单键或具有1至5个碳原子的直链或支链烷基基团，Ar代表吡啶基，苯基，2,3-亚甲二氧基苯基或3,4-亚甲二氧基苯基基团或一个苯基基团，其被一个或多个取代基取代，这些取代基可以相同或不同，选自卤原子，较低烷基基团或较低烷氧基团，R.sub.11代表氢或较低烷基，苯基，二苯甲基，苄基或卤代苄基基团，R.sub.4代表氢或烷基基团，或当一起取时，R.sub.3和R.sub.4代表具有3至6个碳原子并且可选择地被苯基取代或可选择地被##STR2##中断的烷基或烯基基团，R代表氢，烷基基团，环烷基基团，苄基基团或苯基基团，可选择地被一个或多个取代基取代，这些取代基可以相同或不同，选自卤原子和较低烷基，较低烷氧基或硝基基团。本发明的化合物具有出色的药理学性能，特别是钙转运抑制性能，以及心动过缓，降压和抗肾上腺素性能。
• (Phenylalkylaminoalkyloxy)-heteroaryl-compounds, processes and
  申请人：Kali-Chemie Pharma GmbH

  公开号：US05547967A1

  公开（公告）日：1996-08-20

  3-(Phenylalkylaminoalkylozy)-heteroaryl compounds having heart rate lowering and/or anti-ischemic effects, methods for their preparation and pharmaceutical compositions containing them are described. The compounds correspond to the general formula I ##STR1## or to the general formula XXXI ##STR2## in which the substituents have the meanings given the specification.

  描述了具有降低心率和/或抗缺血作用的3-(苯基烷基氨基烷氧基)-杂环芳基化合物，以及其制备方法和含有它们的药物组合物。这些化合物对应于一般式I或一般式XXXI，在这些式中，取代基具有规范中给定的含义。
• Benzazepine derivatives, their pharmaceutical compositions and method of
  申请人：Dr. Karl Thomae Gesellschaft mit beschrankter Haftung

  公开号：US04490369A1

  公开（公告）日：1984-12-25

  Compounds of the formula ##STR1## wherein A is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --NH--CO--, --CH.sub.2 --CO-- or ##STR2## where R.sub.7 is alkyl of 1 to 3 carbon atoms, and B is methylene, carbonyl or thiocarbonyl, or A is --CO--CO--, --N.dbd.CH--, ##STR3## where R.sub.8 is hydrogen or alkyl of 1 to 3 carbon atoms substituted by a phenyl, methoxyphenyl or dimethoxyphenyl, and B is methylene; E is n-alkylene of 2 to 4 carbon atoms optionally substituted by an alkyl of 1 to 3 carbon atoms, 2-hydroxy-n-propylene, 2-hydroxy-n-butylene or 3-hydroxy-n-butylene; G is n-alkylene of 1 to 5 carbon atoms optionally substituted by an alkyl of 1 to 3 carbon atoms, wherein one methylene group of an n-alkylene of 2 to 5 carbon atoms can be replaced by a carbonyl group, with the proviso that B represents a methylene or carbonyl group, or methylene-n-hydroxy-alkylene of 1 to 4 carbon atoms, where the methylene group is attached to the nitrogen atom; and R.sub.1 to R.sub.5 are simple substituents of various types; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.

  式为##STR1##的化合物，其中A为--CH.sub.2 --CH.sub.2 --，--CH.dbd.CH--，--NH--CO--，--CH.sub.2 --CO--或##STR2##，其中R.sub.7为1至3个碳原子的烷基，B为亚甲基，羰基或硫代羰基，或A为--CO--CO--，--N.dbd.CH--，##STR3##其中R.sub.8为氢或1至3个碳原子的烷基，其被苯基，甲氧基苯基或二甲氧基苯基取代，B为亚甲基；E为2至4个碳原子的n-烷基，可选择地被1至3个碳原子的烷基，2-羟基-n-丙烯基，2-羟基-n-丁烯基或3-羟基-n-丁烯基取代；G为1至5个碳原子的n-烷基，可选择地被1至3个碳原子的烷基取代，其中2至5个碳原子的n-烷基的一个亚甲基可以被羰基取代，条件是B代表亚甲基或羰基，或者为1至4个碳原子的亚甲基-n-羟基-烷基，其中亚甲基与氮原子相连；R.sub.1至R.sub.5为各种类型的简单取代基；以及其非毒性、药理学上可接受的酸盐。这些化合物及其盐可用作心动过缓药。
• Aminoalkoxyphenyl derivatives, process of preparation and compositions
  申请人：Sanofi

  公开号：US05147878A1

  公开（公告）日：1992-09-15

  Aminoalkoxyphenyl derivatives useful in the treatment of certain pathological syndromes of the cardiovascular system of formula: ##STR1## in which: B represents a --S, --SO--, or --SO.sub.2 -- group, R.sub.1 and R.sub.2, which are identical or different, each denote hydrogen, a methyl or ethyl radical or a halogen such as chlorine, bromine or iodine, A denotes a straight- or branched-alkylene radical having from 2 to 5 carbon atoms or a 2-hydroxypropylene radical in which the hydroxy is optionally substituted by a lower alkyl radical, Ar represents a group ##STR2## R.sub.4 denotes hydrogen or an alkyl radical and Cy represents a cyclic group.

  氨基烷氧基苯基衍生物在治疗心血管系统某些病理综合征中有用，其化学式为：##STR1## 其中：B代表一个--S、--SO--或--SO.sub.2--基团，R.sub.1和R.sub.2，相同或不同，分别表示氢、甲基或乙基基团或氯、溴或碘等卤素，A表示具有2至5个碳原子的直链或支链烷基基团或2-羟基丙烯基基团，其中羟基可选择性地被较低的烷基基团取代，Ar代表一个基团##STR2## R.sub.4代表氢或烷基基团，Cy代表一个环状基团。
• Anti-arrhythmic agents
  申请人：American Home Products Corporation

  公开号：US04539426A1

  公开（公告）日：1985-09-03

  Compounds of the formula: ##STR1## in which Y is --(CH.sub.2).sub.n -- where n is one of the integers 1,2,3 or 4 or ##STR2## where R is hydrogen, alkyl, polyfluorinated alkyl, --CN, cyanoalkyl, cycloalkyl or cycloalkylalkyl; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen, alkoxy, trifluoromethyl or halo; R.sup.8 is hydrogen or alkyl; R.sup.9 is alkyl; R.sup.10 is alkyl; m is one of the integers 0 or 1; p is one of the integers 0, 1, 2 or 3; and s is one of the integers 0 or 1; or a pharmaceutically acceptable salt thereof, are useful as anti-arrhythmic agents.

  该公式化合物为：##STR1## 其中Y为--(CH.sub.2).sub.n--，其中n为整数1、2、3或4之一，或者##STR2## 其中R为氢、烷基、多氟烷基、--CN、氰基烷基、环烷基或环烷基烷基；R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7，独立地为氢、烷氧基、三氟甲基或卤素；R.sup.8为氢或烷基；R.sup.9为烷基；R.sup.10为烷基；m为整数0或1；p为整数0、1、2或3之一；s为整数0或1之一；或其药学上可接受的盐，可用作抗心律失常药物。